Anna L. Blobaum

发表

P. Jeffrey Conn, Eric S. Dawson, Julie L. Engers, 2013 .

Challenges in the Discovery and Optimization of mGlu2/4 Heterodimer Positive Allosteric Modulators

Anna L. Blobaum, C. Lindsley, C. Niswender, 2019, Letters in drug design & discovery.

Discovery, synthesis, and structure-activity relationship development of a series of N-(4-acetamido)phenylpicolinamides as positive allosteric modulators of metabotropic glutamate receptor 4 (mGlu(4)) with CNS exposure in rats.

Anna L. Blobaum, S. Jadhav, C. Lindsley, 2011, Journal of medicinal chemistry.

Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.

Anna L. Blobaum, J. Javitch, C. Lindsley, 2016, ACS chemical neuroscience.

Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.

Bruce J. Melancon, Anna L. Blobaum, N. Brandon, 2017, ACS medicinal chemistry letters.

N-Alkylpyrido[1',2':1,5]pyrazolo-[4,3-d]pyrimidin-4-amines: A new series of negative allosteric modulators of mGlu1/5 with CNS exposure in rodents.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2016, Bioorganic & medicinal chemistry letters.

Discovery and characterization of a novel series of N-phenylsulfonyl-1H-pyrrole picolinamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4).

Anna L. Blobaum, C. Lindsley, C. Hopkins, 2016, Bioorganic & medicinal chemistry letters.

Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2′-Des-methyl-sulindac Sulfide Scaffold

Lawrence J. Marnett, Anna L. Blobaum, L. Marnett, 2012, Journal of medicinal chemistry.

Species-Specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the Metabolism of the Pyrimidine-Containing mGlu5-Negative Allosteric Modulator VU0424238 (Auglurant)

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2017, Drug Metabolism and Disposition.

Further exploration of an N-aryl phenoxyethoxy pyridinone-based series of mGlu3 NAMs: Challenging SAR, enantiospecific activity and in vivo efficacy.

Anna L. Blobaum, C. Lindsley, C. Niswender, 2019, Bioorganic & medicinal chemistry letters.

Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu3 NAMs.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2017, ACS medicinal chemistry letters.

Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators

Anna L. Blobaum, J. Cheer, C. Lindsley, 2018, Molecular Psychiatry.

Discovery of VU0409106: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety.

Andrew S. Felts, Brittney S. Bates, Anna L. Blobaum, 2013, Bioorganic & medicinal chemistry letters.

Structural and Functional Basis of Cyclooxygenase Inhibition

Anna L. Blobaum, L. Marnett, Anna L Blobaum, 2007 .

Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992

Amanda M. Duran, Anna L. Blobaum, J. Meiler, 2018, Molecular Pharmacology.

Discovery and Optimization of a Novel Series of Competitive and Central Nervous System-Penetrant Protease-Activated Receptor 4 (PAR4) Inhibitors.

Anna L. Blobaum, H. Hamm, J. Meiler, 2021, ACS chemical neuroscience.

Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets

Anna L. Blobaum, H. Hamm, C. Lindsley, 2017, Molecular Pharmacology.

Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.

Anna L. Blobaum, C. Lindsley, Hyekyung P. Cho, 2017, Journal of medicinal chemistry.

Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic Analysis.

Anna L. Blobaum, W. D. Nes, M. Botta, 2018, Journal of medicinal chemistry.

Formation of a novel reversible cytochrome P450 spectral intermediate: role of threonine 303 in P450 2E1 inactivation.

Anna L. Blobaum, Shaomeng Wang, Yipin Lu, 2004, Biochemistry.

Discovery of 4-alkoxy-6-methylpicolinamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2019, Bioorganic & medicinal chemistry letters.

Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2018, Bioorganic & medicinal chemistry letters.

Development and kilogram-scale synthesis of mGlu5 negative allosteric modulator VU0424238 (auglurant)

Anna L. Blobaum, C. Lindsley, P. Conn, 2017 .

Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2017, Bioorganic & medicinal chemistry letters.

Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.

Anna L. Blobaum, H. Hamm, C. Lindsley, 2016, Journal of medicinal chemistry.

MECHANISM-BASED INACTIVATION AND REVERSIBILITY : IS THERE A NEW TREND IN THE INACTIVATION OF CYTOCHROME P 450 ENZYMES ?

Anna L. Blobaum, 2005 .

Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.

Anna L. Blobaum, W. D. Nes, C. Lindsley, 2018, Journal of medicinal chemistry.

Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia.

Bruce J. Melancon, Anna L. Blobaum, D. Sheffler, 2013, Bioorganic & medicinal chemistry letters.

Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256.

S. P. Moran, Anna L. Blobaum, C. Lindsley, 2016, ACS chemical neuroscience.

Discovery of a potent M5 antagonist with improved clearance profile. Part 1: piperidine amide-based antagonists.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2022, Bioorganic & medicinal chemistry letters.

Optimization of the choline transporter (CHT) inhibitor ML352: Development of VU6001221, an improved in vivo tool compound.

Anna L. Blobaum, R. Blakely, C. Lindsley, 2016, Bioorganic & medicinal chemistry letters.

Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core.

Anna L. Blobaum, C. Lindsley, Hyekyung P. Cho, 2015, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents†

M. J. Uddin, Anna L. Blobaum, L. Marnett, 2009 .

Development and profiling of mGlu7 NAMs with a range of saturable inhibition of agonist responses in vitro.

Anna L. Blobaum, C. Lindsley, C. Niswender, 2022, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of a series of mGlu7 NAMs based on an ethyl-8-methoxy-4-(4-phenylpiperazin-1-yl)quinoline carboxylate core.

Anna L. Blobaum, C. Lindsley, P. Conn, 2020, Bioorganic & medicinal chemistry letters.

Discovery of VU6027459: A First-in-Class Selective and CNS Penetrant mGlu7 Positive Allosteric Modulator Tool Compound.

Anna L. Blobaum, C. Lindsley, P. Conn, 2020, ACS medicinal chemistry letters.

Surveying heterocycles as amide bioisosteres within a series of mGlu7 NAMs: Discovery of VU6019278.

Anna L. Blobaum, C. Lindsley, C. Niswender, 2019, Bioorganic & medicinal chemistry letters.

Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu7 Negative Allosteric Modulator (NAM) in Vivo Tool Compound: N-(2-(1 H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962).

Anna L. Blobaum, C. Lindsley, P. Conn, 2019, Journal of medicinal chemistry.

Discovery of Novel Central Nervous System Penetrant Metabotropic Glutamate Receptor Subtype 2 (mGlu2) Negative Allosteric Modulators (NAMs) Based on Functionalized Pyrazolo[1,5- a]pyrimidine-5-carboxamide and Thieno[3,2- b]pyridine-5-carboxamide Cores.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2018, Journal of medicinal chemistry.

Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liability.

Alison R. Gregro, Julie L. Engers, Anna L. Blobaum, 2018, Bioorganic & medicinal chemistry letters.

VU6010608, a Novel mGlu7 NAM from a Series of N-(2-(1H-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)benzamides.

Anna L. Blobaum, C. Lindsley, P. Conn, 2017, ACS medicinal chemistry letters.

Discovery of VU6005649, a CNS Penetrant mGlu7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-a]pyrimidines.

Anna L. Blobaum, C. Lindsley, P. Conn, 2017, ACS medicinal chemistry letters.

Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core.

Julie L. Engers, Andrew S. Felts, Anna L. Blobaum, 2017, ACS medicinal chemistry letters.

VU6010608, a Novel mGlu 7 NAM from a Series of N ‑ (2-(1 H ‑ 1,2,4-Triazol-1-yl)-5-(tri ﬂ uoromethoxy)phenyl)benzamides

Anna L. Blobaum, C. Lindsley, C. Niswender, 2017 .

Re-exploration of the mGlu₁ PAM Ro 07-11401 scaffold: Discovery of analogs with improved CNS penetration despite steep SAR.

Anna L. Blobaum, C. Lindsley, Hyekyung P. Cho, 2016, Bioorganic & medicinal chemistry letters.

Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 3. Engineering plasma stability by discovery and optimization of isoindolinone analogs.

Anna L. Blobaum, C. Lindsley, Hyekyung P. Cho, 2016, Bioorganic & medicinal chemistry letters.

Lead optimization of the VU0486321 series of mGlu(1) PAMs. Part 2: SAR of alternative 3-methyl heterocycles and progress towards an in vivo tool.

Anna L. Blobaum, C. Lindsley, Hyekyung P. Cho, 2016, Bioorganic & medicinal chemistry letters.

Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics

Anna L. Blobaum, Z. Xiang, C. Lindsley, 2015, Journal of medicinal chemistry.

Development of VU6019650: A Potent, Highly Selective, and Systemically Active Orthosteric Antagonist of the M5 Muscarinic Acetylcholine Receptor for the Treatment of Opioid Use Disorder.

Andrew S. Felts, Anna L. Blobaum, N. Schnetz-Boutaud, 2022, Journal of medicinal chemistry.

Synthesis and evaluation of carbaborane derivatives of indomethacin as cyclooxygenase inhibitors.

Anna L. Blobaum, L. Marnett, E. Hey‐Hawkins, 2011, Bioorganic & medicinal chemistry.

Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu₄.

Anna L. Blobaum, C. Lindsley, C. Hopkins, 2011, ACS combinatorial science.

A Novel M1 PAM VU0486846 Exerts Efficacy in Cognition Models without Displaying Agonist Activity or Cholinergic Toxicity.

S. P. Moran, Anna L. Blobaum, C. Lindsley, 2018, ACS chemical neuroscience.

Ortho-carbaborane derivatives of indomethacin as cyclooxygenase (COX)-2 selective inhibitors.

Lawrence J Marnett, Evamarie Hey-Hawkins, Anna L. Blobaum, 2012, Bioorganic & medicinal chemistry.

The 2′-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor

Andrew S. Felts, M. J. Uddin, Anna L. Blobaum, 2013, ACS medicinal chemistry letters.

Isoform selective PLD inhibition by novel, chiral 2,8-diazaspiro[4.5]decan-1-one derivatives.

Sarah A. Scott, Anna L. Blobaum, A. Waterson, 2018, Bioorganic & medicinal chemistry letters.

Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkins

Anna L. Blobaum, Y. Smith, S. Jadhav, 2011, Journal of medicinal chemistry.

Cyclooxygenase Inhibition Mechanisms: Recent Advances

Anna L. Blobaum, L. Marnett, Anna L Blobaum, 2008 .

Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles.

Anna L. Blobaum, H. Hamm, C. Lindsley, 2016, Bioorganic & medicinal chemistry letters.

The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu4 PAM development candidate.

Alison R. Gregro, Andrew S. Felts, Anna L. Blobaum, 2019, Bioorganic & medicinal chemistry letters.

Discovery, Structure-Activity Relationship, and Biological Characterization of a Novel Series of 6-((1 H-Pyrazolo[4,3- b]pyridin-3-yl)amino)-benzo[ d]isothiazole-3-carboxamides as Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 4 (mGlu4).

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2018, Journal of medicinal chemistry.

Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).

Anna L. Blobaum, J. Macor, C. Lindsley, 2016, ACS chemical neuroscience.

Structural and functional basis of cyclooxygenase inhibition.

Lawrence J Marnett, Anna L. Blobaum, L. Marnett, 2007, Journal of medicinal chemistry.

Multi-log cytotoxicity of carbocyclic 2'-deoxyguanosine in HSV-TK-expressing human tumor cells.

Anna L. Blobaum, L. Zerbe, W. Parker, 2002, Human gene therapy.

Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein.

Anna L. Blobaum, P. Hollenberg, Anna L Blobaum, 2002, Chemical research in toxicology.

Structure-Activity Relationships, Pharmacokinetics, and Pharmacodynamics of the Kir6.2/SUR1-Specific Channel Opener VU0071063

Anna L. Blobaum, Elaine L. Shelton, C. Lindsley, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Structure-Activity Relationships, Pharmacokinetics, and Pharmacodynamics of the Kir6.2/SUR1-Specific Channel Opener VU0071063 s

Anna L. Blobaum, Elaine L. Shelton, C. Lindsley, 2019 .

The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease

Anna L. Blobaum, M. Amalric, S. Jadhav, 2012, Journal of Pharmacology and Experimental Therapeutics.

The mechanism-based inactivation of p450 2B4 by tert-butyl 1-methyl-2-propynyl ether: structural determination of the adducts to the p450 heme.

Anna L. Blobaum, P. Hollenberg, L. V. von Weymarn, 2004, Archives of biochemistry and biophysics.

MECHANISM-BASED INACTIVATION AND REVERSIBILITY: IS THERE A NEW TREND IN THE INACTIVATION OF CYTOCHROME P450 ENZYMES?

Anna L. Blobaum, 2006, Drug Metabolism and Disposition.

P450 active site architecture and reversibility: inactivation of cytochromes P450 2B4 and 2B4 T302A by tert-butyl acetylenes.

Anna L. Blobaum, P. Hollenberg, D. Harris, 2005, Biochemistry.

Novel Reversible Inactivation of Cytochrome P450 2E1 T303A by tert-Butyl Acetylene: The Role of Threonine 303 in Proton Delivery to the Active Site of Cytochrome P450 2E1

Anna L. Blobaum, P. Hollenberg, Anna L Blobaum, 2004, Journal of Pharmacology and Experimental Therapeutics.

Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM.

Cody J. Wenthur, Anna L. Blobaum, D. Sheffler, 2012, Bioorganic & medicinal chemistry letters.

Heterotropic Activation of the Midazolam Hydroxylase Activity of CYP3A by a Positive Allosteric Modulator of mGlu5: In Vitro to In Vivo Translation and Potential Impact on Clinically Relevant Drug-Drug Interactions

Anna L. Blobaum, G. Macdonald, H. Lavreysen, 2013, Drug Metabolism and Disposition.

Microsoft Word-JSD_3A4_activation_mGlu5_PAM_revised_final_V4[1]

Anna L. Blobaum, G. Macdonald, H. Lavreysen, 2013 .

DMD052662 2066..2075

Anna L. Blobaum, G. Macdonald, H. Lavreysen, 2013 .

mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome

Anna L. Blobaum, Z. Xiang, C. Lindsley, 2017, Science Translational Medicine.

Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169.

Anna L. Blobaum, D. Sheffler, C. Lindsley, 2012, ACS chemical neuroscience.

Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2017, ACS chemical neuroscience.

A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo

Anna L. Blobaum, C. Lindsley, P. Conn, 2015, Drug Metabolism and Disposition.

ML418: The First Selective, Sub-Micromolar Pore Blocker of Kir7.1 Potassium Channels.

Anna L. Blobaum, J. Meiler, C. Lindsley, 2016, ACS chemical neuroscience.

Octahydropyrrolo[3,4-c]pyrrole negative allosteric modulators of mGlu1.

Anna L. Blobaum, C. Lindsley, Hyekyung P. Cho, 2013, Bioorganic & medicinal chemistry letters.

Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain

Anna L. Blobaum, Qian Xu, Shaoqiu He, 2017, Proceedings of the National Academy of Sciences.

Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.

Julie L. Engers, Andrew S. Felts, Anna L. Blobaum, 2018, ACS medicinal chemistry letters.

Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2015, Journal of medicinal chemistry.

Persistent challenges in the development of an mGlu7 PAM in vivo tool compound: The discovery of VU6046980.

Anna L. Blobaum, O. Boutaud, C. Lindsley, 2022, Bioorganic & medicinal chemistry letters.

Action at a Distance

Anna L. Blobaum, L. Marnett, Shu Xu, 2015, The Journal of Biological Chemistry.

Discovery of VU6015929: A Selective Discoidin Domain Receptor 1/2 (DDR1/2) Inhibitor to Explore the Role of DDR1 in Antifibrotic Therapy.

Anna L. Blobaum, A. Pozzi, C. Lindsley, 2019, ACS medicinal chemistry letters.

Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor.

Anna L. Blobaum, D. Sheffler, C. Lindsley, 2012, Bioorganic & medicinal chemistry letters.

The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives.

Andrew S. Felts, Anna L. Blobaum, L. Marnett, 2009, Bioorganic & medicinal chemistry letters.

Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics

Anna L. Blobaum, T. Lybrand, L. Marnett, 2015, Biochemistry.

Molecular Determinants for the Selective Inhibition of Cyclooxygenase-2 by Lumiracoxib*

Anna L. Blobaum, L. Marnett, Anna L Blobaum, 2007, Journal of Biological Chemistry.

Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Lawrence J Marnett, M. J. Uddin, David W Piston, 2010, Cancer research.

Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates

Anna L. Blobaum, M. Nader, P. Newhouse, 2020, Neuropsychopharmacology.

NSAID Action and the Foundations for Cardiovascular Toxicity

Anna L. Blobaum, L. Marnett, Anna L Blobaum, 2010 .

Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.

Julie L. Engers, Andrew S. Felts, Anna L. Blobaum, 2015, Journal of medicinal chemistry.

Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration.

Anna L. Blobaum, C. Lindsley, P. Conn, 2016, Bioorganic & medicinal chemistry letters.

The Role of Aldehyde Oxidase and Xanthine Oxidase in the Biotransformation of a Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5

Andrew S. Felts, Brittney S. Bates, Anna L. Blobaum, 2012, Drug Metabolism and Disposition.

The Role of Aldehyde Oxidase and Xanthine Oxidase in the Biotransformation of a Novel Negative Allosteric Modulator of mGlu5

Andrew S. Felts, Brittney S. Bates, Anna L. Blobaum, 2012 .

Discovery, synthesis and characterization of a series of 7-aryl-imidazo[1,2-a]pyridine-3-ylquinolines as activin-like kinase (ALK) inhibitors.

Andrew S. Felts, Anna L. Blobaum, C. Lindsley, 2020, Bioorganic & medicinal chemistry letters.

Discovery of a Novel Class of Heteroaryl-Pyrrolidinones as Positive Allosteric Modulators of the Muscarinic Acetylcholine Receptor M1.

Anna L. Blobaum, O. Boutaud, C. Lindsley, 2021, Bioorganic & medicinal chemistry letters.

The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core.

Anna L. Blobaum, C. Lindsley, Hyekyung P. Cho, 2018, Bioorganic & medicinal chemistry letters.

The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU 0364770 Produces Efficacy Alone and in Combination with L-DOPA or an Adenosine 2 A Antagonist in Preclinical Rodent Models of Parkinson ’ s Disease

Anna L. Blobaum, M. Amalric, S. Jadhav, 2012 .

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2018, Journal of Medicinal Chemistry.

Discovery and optimization of a novel CNS penetrant series of mGlu4 PAMs based on a 1,4-thiazepane core with in vivo efficacy in a preclinical Parkinsonian model.

Anna L. Blobaum, O. Boutaud, C. Lindsley, 2021, Bioorganic & medicinal chemistry letters.

Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation

Andrew S. Felts, Brittney S. Bates, Anna L. Blobaum, 2017, Journal of medicinal chemistry.

Development of the First Selective mGlu3 NAM from an mGlu5 PAM Hit

Julie L. Engers, Joshua A. Brunner, Anna L. Blobaum, 2013 .

Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 4: SAR reveals positive cooperativity across multiple mGlu receptor subtypes leading to subtype unselective PAMs.

Anna L. Blobaum, O. Boutaud, C. Lindsley, 2020, Bioorganic & medicinal chemistry letters.

VU6007477, a Novel M1 PAM Based on a Pyrrolo[2,3-b]pyridine Carboxamide Core Devoid of Cholinergic Adverse Events.

Julie L. Engers, Anna L. Blobaum, C. Lindsley, 2018, ACS medicinal chemistry letters.